Elicio Therapeutics

Elicio Therapeutics

Biotechnology, 1 Kendall Sq, Boston, Massachusetts, 02139, United States, 11-50 Employees

elicio.com

  • LinkedIn

phone no Phone Number: 16*********

Who is ELICIO THERAPEUTICS

Elicio is committed to transforming the lives of patients and their families by re-engineering the bodys immune response to cancer. By combining expertise in materials science and immunol...

Read More

map
  • 1 Kendall Sq, Boston, Massachusetts, 02139, United States Headquarters: 1 Kendall Sq, Boston, Massachusetts, 02139, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from ELICIO THERAPEUTICS

Elicio Therapeutics Org Chart and Mapping

Employees

Michael Divecchia

Senior Vice President of Operations & Human Resources

Peter Demuth

Chief Scientific Officer

Erica Palmer

Senior Research Associate

Teresa Bailey

Senior Clinical Trial Manager

Amy Tavares

Senior Research Associate

Chandni Goyal

Assistant Director of Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Elicio Therapeutics

Answer: Elicio Therapeutics's headquarters are located at 1 Kendall Sq, Boston, Massachusetts, 02139, United States

Answer: Elicio Therapeutics's phone number is 16*********

Answer: Elicio Therapeutics's official website is https://elicio.com

Answer: Elicio Therapeutics's revenue is $10 Million to $25 Million

Answer: Elicio Therapeutics's SIC: 2834

Answer: Elicio Therapeutics has 11-50 employees

Answer: Elicio Therapeutics is in Biotechnology

Answer: Elicio Therapeutics contact info: Phone number: 16********* Website: https://elicio.com

Answer: Elicio is committed to transforming the lives of patients and their families by re-engineering the bodys immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the brain center of the immune response, to significantly amplify and enhance the bodys own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio's lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicios Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access